Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • FAQs

    Gastrointestinal Stents Market size was valued at USD 5.29 Billion in 2024 and is poised to grow from USD 5.58 Billion in 2025 to USD 8.56 Billion by 2033, growing at a CAGR of 5.5% during the forecast period (2026–2033).

    The global gastrointestinal stents market is highly competitive and characterized by the presence of several established and emerging players. These companies are engaged in developing and manufacturing gastrointestinal stents used in various medical applications. Gastrointestinal stents are widely utilized in the treatment of various gastrointestinal disorders and obstructions, offering a minimally invasive alternative to traditional surgical procedures. 'Boston Scientific Corporation (USA) ', 'BD (Becton, Dickinson and Company) (USA) ', 'Cook Medical (USA) ', 'Olympus Corporation (Japan) ', 'Merit Medical Systems (USA) ', 'CONMED Corporation (USA) ', 'ELLA-CS s.r.o. (Czech Republic) ', 'Hobbs Medical Inc. (USA) ', 'Taewoong Medical Co. Ltd. (South Korea) ', 'S&G Biotech Inc. (South Korea) ', 'Medtronic (Ireland) ', 'AbbVie (USA) ', 'Johnson & Johnson (USA) ', 'Takeda Pharmaceutical Company Limited (Japan) ', 'Pfizer Inc. (USA) ', 'Novartis AG (Switzerland) ', 'Bayer AG (Germany) ', 'AstraZeneca plc (UK) ', 'Roche Holding AG (Switzerland) ', 'Eli Lilly and Company (USA)'

    Growing awareness among patients and healthcare providers about the benefits of gastrointestinal stents has resulted in early diagnosis and timely intervention. Furthermore, improved access to healthcare facilities in developing regions has increased the adoption of stenting procedures, propelling market expansion.

    Increasing Preference for Biodegradable Stents: Biodegradable gastrointestinal stents offer several advantages over traditional metallic stents, making them an emerging and attractive option for medical practitioners and patients alike. These stents are typically made from materials that gradually dissolve over time, eliminating the need for an additional removal procedure, which is often required with permanent metallic stents. This feature reduces the risk of complications and offers a more convenient and patient-friendly treatment option. Furthermore, biodegradable stents can provide temporary support to the diseased area during the healing process, gradually losing their structural integrity as the tissue heals and regenerates.

    North America emerges as the most dominant region in the global gastrointestinal stents market. The dominance of North America can be attributed to several factors. Firstly, the region has a well-established healthcare infrastructure and a high level of awareness about advanced medical treatments. Secondly, there is a substantial patient pool suffering from gastrointestinal disorders, including colorectal cancer, esophageal cancer, and benign strictures.

    Feedback From Our Clients

    Global Gastrointestinal Stents Market

    Report ID: SQMIG35A2398

    $5,300
    BUY NOW